Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25Progression of preclinical next-generation ...
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships wit ...
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...
Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & CompanyTwo lead programs in ...
We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...
The Association of Cancer Care Centers (ACCC), in collaboration with Eli Lilly and Company, is pleased to announce the seven recipients of the "Improving the Precision Oncology Care Pathway" Request ...
A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...
The S&P 500 (SNPINDEX: ^GSPC) is cooling off after rip-roaring gains of over 20% in both 2023 and 2024. The Nasdaq Composite ...
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
An estimated 6 to 17 percent of children have sleep-disordered breathing, ranging from snoring to sleep apnea, which can cause behavioral, neurocognitive, cardiovascular, and cardiometabolic issues. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback